September 16, 2011

HELIX BIOPHARMA CORP. TO PRESENT AT THE TWENTY SEVENTH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE AND CLINICAL WORKSHOP (PDF)

AURORA, Ontario, September 16, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), (“Helix” or the
“Company”), a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced
that Praveen Kumar, Ph.D., Vice President, Topical Drug Product Development, will be presenting at the Twenty Seventh
International Papillomavirus Conference and Clinical Workshop which runs from September 16 to September 22, 2011 at the
International Congress Center in Berlin, Germany.